In this episode, David Drapkin interviews Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS), Rick Doblin, Ph.D. MAPS has recently been at the center of media scrutiny, notably through New York magazine’s “Cover Story” podcast series, which chronicled instances of alleged sexual abuse within the MAPS clinical MDMA trials. We wanted to provide an opportunity for Doblin to respond to these very real concerns, and he does just that, discussing how MAPS reacted; what could have been done better; what this has all meant for MAPS; and how it feels to suddenly be seen by many as an enemy in a space they helped build. He also discusses what the post-approval psychedelic landscape could look like; their goals for facilitator training and how they align with requirements in Oregon; their desire for a patient registry or “global trauma index”; and the importance of collecting and analyzing real-world evidence. And he talks about MAPS and their globalization goals: how exploring psychedelic therapy specifically in countries with little to no tradition of psychotherapy can lead to new therapeutic models.

The post PT327 – Rick Doblin, Ph.D. – Confronting Abuse in Clinical Trials and the Future of Psychedelic Medicine appeared first on Psychedelics Today.

Previous articlePsychedelic Bulletin #106 – DMT Study Skips Set and Setting; Cybin Acquires Phase 1 Study; FDA Snubs Seamless Trial Design
Next articleExploring Ketamine’s Antimicrobial Effects & Fungal Sources: Part 1